GlobeImmune Announces Updates
17. November 2016 17:49 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - November 17, 2016) - GlobeImmune, Inc. today provided an update on the Company's business:Gilead Sciences, Inc. has terminated the collaboration and license agreement...
GlobeImmune Announces Delisting and Deregistration of Common Stock
05. Juli 2016 16:30 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - July 05, 2016) - GlobeImmune, Inc. (NASDAQ: GBIM) On June 30, 2016, the board of directors (the "Board") of GlobeImmune, Inc. (the "Company") made a determination to...
GlobeImmune Announces Updates and Financial Results for First Quarter 2016
12. Mai 2016 06:30 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - May 12, 2016) -
GlobeImmune, Inc. (NASDAQ: GBIM) today provided an update on the Company's business and clinical programs and announced financial results for...
GlobeImmune Announces Updates and Financial Results for Full Year 2015
16. März 2016 06:30 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - March 16, 2016) -
GlobeImmune, Inc. (NASDAQ: GBIM) today provided an update on the Company's business and clinical programs and announced financial results for...
GlobeImmune Announces Third Quarter 2015 Results and Corporate Highlights
13. November 2015 06:30 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - November 13, 2015) - GlobeImmune, Inc. (NASDAQ: GBIM), a biopharmaceutical company focused on developing products for the treatment of cancer and infectious diseases...
GlobeImmune Announces Second Quarter 2015 Results and Corporate Highlights
14. August 2015 06:30 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - August 14, 2015) - GlobeImmune, Inc. (NASDAQ: GBIM), a biopharmaceutical company focused on developing products for the treatment of cancer and infectious diseases...
GlobeImmune Engages Cantor Fitzgerald as Financial Advisor to Assist With Evaluation of Strategic Options
13. August 2015 06:30 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - August 13, 2015) - GlobeImmune, Inc. (NASDAQ: GBIM), a biopharmaceutical company focused on developing products for the treatment of cancer and infectious diseases...
UPDATE - Celgene Exercises Early Option to Exclusively License GI-6207, a Novel Cancer Immunotherapy
04. August 2015 09:27 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - August 04, 2015) - GlobeImmune, Inc. (NASDAQ: GBIM) announced today that Celgene Corporation exercised its option under the 2009 Collaboration and Option Agreement to...
Celgene Exercises Early Option to Exclusively License GI-6207, a Novel Cancer Immunotherapy
04. August 2015 06:30 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - August 04, 2015) - GlobeImmune, Inc. announced today that Celgene Corporation exercised its option under the 2009 Collaboration and Option Agreement to exclusively...
GlobeImmune Announces Evaluation of Strategic Alternatives and Corporate Restructuring
10. Juni 2015 06:30 ET
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - June 10, 2015) - GlobeImmune, Inc. (NASDAQ: GBIM) today announced that it is evaluating strategic options for the company. In conjunction with this process, the Board...